3/28/2022 8:54:35 AM
CorMedix Reports FDA Acceptance Of Resubmission Of New Drug Application For DefenCath
3/17/2022 8:53:15 AM
CorMedix Inc. Appoints Joseph Todisco As CEO
3/15/2021 8:41:26 AM
CorMedix Says Approved To Sell $1.3 Mln Of NOL Tax Benefits Through NJEDA
3/3/2016 8:15:43 AM
FBR Capital Markets Starts CorMedix Inc. (CRMD) At Outperform With $7 Price Target